Type I reaction of Hansen's disease with exposure to adalimumab: A case report

Elana M. Oberstein, Olga Kromo, Elaine C. Tozman

Arthritis Care & Research · 2008 · 26 citations · 12 references

Concepts

Abstract

Tumor necrosis factor α (TNFα) is a proinflammatory cytokine that has an important role in inflammatory diseases. Three biologic anti-TNFα agents are approved for clinical use in rheumatoid arthritis (RA), psoriatic arthritis, and seronegative arthropathies: 2 monoclonal antibodies, infliximab and adalimumab, and the fusion protein etanercept (1). These drugs are commonly used in patients whose disease is incompletely controlled with methotrexate. Although such medications have revolutionized the lives of patients with inflammatory arthritis by decreasing symptoms and increasing functional status, safety concerns regarding increased risk of infectious diseases and reactivation of tuberculoid disease have limited patient selection (1). New onset or severe exacerbation of psoriasis is a rare complication of TNFα inhibitor therapy (2). A 47-year-old man from the Amazon region of Brazil who had no past medical illness presented with symmetric polyarticular joint pain and swelling of both hands and wrists for 6–8 weeks (Figure 1A). He reported similar involvement of his elbows and ankles bilaterally. The patient had no prior fever, chills, cough, or dyspnea. There was no history of weight loss, night sweats, headaches, chest pain, or other systemic symptoms. There was no family history of rheumatic diseases. Radiographic imaging of the hands and wrists showed diffuse soft tissue swelling, periarticular osteopenia, and no evidence of underlying bony abnormality. Due to inability to function, the patient was started on daily oral prednisone (10 mg) while further evaluation was performed. A, Bilateral hands with multiple swollen metacarpophalangeal and proximal interphalangeal joint synovitis. B, Anterior chest with various plaques. Laboratory analysis revealed an elevated C-reactive protein (CRP) level of 3.6 mg/dl (normal range 0 to <1.0 mg/dl) and an erythrocyte sedimentation rate (ESR) of 27 mm/hour (normal range 0–20 mm/hour). Anti–cyclic citrullinated peptide antibody and rheumatoid factor were negative, and antibody analysis for viral hepatitis revealed no active or past infection. Seronegative RA was diagnosed and methotrexate 10 mg weekly was started and was increased to 15 mg and later 20 mg weekly, with clinical and laboratory improvement (CRP 0.5 mg/dl and ESR 8 mm/hour). Prednisone was tapered completely as the dose of methotrexate was increased. Six months after the initial presentation, after a chest radiograph and purified protein derivative skin test were unremarkable, adalimumab was added (40 mg subcutaneously every 2 weeks). After 1 month of combined therapy, the patient developed synovitis and marked swelling of the pinnae and a diffuse rash with multiple well-defined annular macular lesions with erythematous borders, occasional central clearing, and silvery scales over the thorax and upper extremities (Figure 1B). Biopsy samples of the pinnae and rash were obtained and the patient was started on oral prednisone (1mg/kg, total of 60 mg) for presumed psoriasiform epidermal reaction with possible polychondritis. The biopsy samples revealed lymphohistiocytic infiltration with granuloma formation and presence of mycobacteria consistent with tuberculoid leprosy (Figure 2). On further questioning, the patient did recall that several residents of his hometown carried the diagnosis of Hansen's disease. TNFα inhibition was discontinued and triple therapy for borderline lepromatous leprosy was started with clofazimine, dapsone, and rifampin. He is currently doing well on triple therapy for Hansen's disease and is not receiving a disease-modifying antirheumatic drug. A, Hematoxylin and eosin stain of lymphohistiocytic infiltration with granuloma formation and giant cells. B, Modified Ziehl-Neelsen stain of acid-fast mycobacteria bacilli clumped into globi. Mycobacterium leprae, the causative agent of Hansen's disease, was first described in 1873. The lapse of time between exposure to this organism and overt expression of the disease varies and may even be decades in some cases (3). M leprae causes a chronic granulomatous disease with highly variable clinical presentations, ranging from an area of desensitized hypopigmented skin to severe damage to nerves and other organs, including bones and joints. The definitive musculoskeletal manifestations of leprosy are neuropathic (Charcot) joints, bacterial arthritis, acute polyarthritis, and chronic rheumatoid-like symmetric peripheral polyarthritis (4). Additionally, inflammatory joint manifestations can be seen in patients with all types of leprosy and may be the presenting symptom. Synovial biopsy specimens reveal a neutrophilic predominance and the presence of epithelioid cell granulomas. The histology is not uniform and may lack infiltration by the lepra bacilli (5). The majority of musculoskeletal manifestations seem to occur only during lepra reactions, typically type I reactions, in patients with borderline or paucibacillary disease or type II reactions in patients with lepromatous leprosy (6, 7). A chronic, relapsing, seronegative, symmetrical, inflammatory, peripheral polyarthritis affecting primarily the wrists, metacarpal and proximal interphalangeal joints of the hands, knees, and metatarsophalangeal joints of the feet associated with leprosy has been described (8, 9). Interestingly, leprosy may present with findings that mimic other rheumatic diseases. For example, subcutaneous granulomatous nodules may cause a wrong diagnosis of RA. A saddlenose deformity, secondary to granulomatous infiltration, may suggest a diagnosis of polychondritis or Wegener's vasculitis. Leprosy should be considered in the differential diagnosis when a clinician encounters these signs. The recent increase in the clinical use of TNFα antagonists for inflammatory arthritis has been accompanied by increased reporting of infectious complications. A study by Wallis et al (10) looking at the data from the Food and Drug Administration (FDA) Adverse Event Reporting System over a 4.75-year period showed an incidence of granulomatous disease of 238.6 per 100,000 patients treated with infliximab and 73.5 per 100,000 patients treated with etanercept. Of the mycobacterial infections, 60.2%, 5.4%, and 0.1% in the monoclonal antibody group and 46.9%, 8.4%, and 0.0% in the soluble receptor group were M tuberculosis, Mycobacterium species (not specified), and M leprae, respectively (10). A recent FDA review of the data from completed clinical trials of etanercept, infliximab, and adalimumab in patients with RA showed an incidence of 0%, 1%, and 0.6%, respectively, of M tuberculosis infection during treatment (11). Multiple mechanisms for increased risk of infection with the use of TNFα inhibitors have been proposed: inhibition of interferon-γ production, decreased expression of pattern-recognition receptors, and leukocyte apoptosis (12). In 2007, Plessner et al demonstrated decreased penetration into the granulomas by the soluble receptor molecule as compared with the antibody in a murine model of tuberculosis, which could shed light on the difference in the rates of M tuberculosis reactivation between the 2 types of biologic agents (13). In 2006, Scollard et al reported 2 cases of leprosy developing after treatment with infliximab for inflammatory arthritis (14). After discontinuation of infliximab, both patients developed type 1 (reversal) lepra reactions. Interestingly, infliximab has been used to treat recurrent erythema nodosum leprosum (15), a toxic syndrome associated with excess TNFα production. In addition, thalidomide has been shown to reduce the half-life of TNFα messenger RNA (16) and is used as a therapy for the erythema nodosum leprosum reaction. It is puzzling that there is clinical and histologic evidence of M leprae initiation or reactivation when TNFα levels are decreased. This underscores the fact that the role of cytokines in the immunopathology of leprosy is ill defined. We believe this patient had an inflammatory arthritis of leprosy presenting as seronegative RA. He experienced a type I reaction of leprosy after anti-TNFα therapy exposure. What is unique about our patient's presentation is the severity of the stage of leprosy at the diagnosis of M leprae infection. Our patient lacked systemic symptoms of leprosy prior to the onset of his joint findings. Also of note is the rheumatoid-like presentation as the first indication of disease, because joint involvement is typically seen later in the course of the infection and is rarely the first symptom. The onset of a plaque-like skin rash after starting adalimumab served to further mask the patient's true diagnosis. Psoriasiform skin reactions during initiation and maintenance of anti-TNFα therapy have been well documented and seen in our clinics (2). There is 1 case report of a patient presenting with intermittent inflammatory polyarthritis associated with fevers who was subsequently diagnosed with borderline leprosy (17). Another report described a patient with rheumatoid-like manifestations of indeterminate leprosy that delayed the actual diagnosis (18). Two cases of M leprae as the cause of arthritis and the initial presentation of the disease in pediatric patients were reported in England (19). To our knowledge, this is the first case in the rheumatology literature of a patient presenting with an inflammatory polyarthritis who experienced a type I reaction of M leprae after exposure to adalimumab. In addition to screening for M tuberculosis prior to initiating anti-TNF therapy, clinicians must consider unusual infections in patients from our global community with previous exposure to various infectious diseases. It is imperative that any rash that presents when a patient is receiving TNFα inhibition be investigated by biopsy because an uncommon etiology may be revealed, as illustrated in this case. Dr. Oberstein had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study design. Oberstein. Acquisition of data. Oberstein, Kromo. Analysis and interpretation of data. Oberstein, Kromo, Tozman. Manuscript preparation. Oberstein, Kromo, Tozman.

References

12